Cisplatin-Eligible, -Ineligible Population Analysis From EV-302

Michiel van der Heijden, MD, PhD, of Netherlands Cancer Institute, and Amanda Nizam, MD, of Cleveland Clinic, contextualize the significance of the subanalyses of the cisplatin-eligible and -ineligible populations from the EV-302 study.

At ESMO 2023, the EV-302 study was initially presented. It evaluated enfortumab vedotin with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma.